Allist Pharmaceuticals released its 2026 interim report, with first-half net profit attributable to the parent company of 1.54 billion yuan, up 46.6% year on year. Operating revenue was 3.32 billion yuan, up 39.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 1.37 billion yuan, up 51.0% year on year. Net operating cash flow was 1.445 billion yuan, up 32.2% year on year. Second-quarter operating revenue was 1.74 billion yuan, up 36.1% year on year, and net profit attributable to the parent was 905 million yuan, up 41.2% year on year. The company said that during the reporting period it focused on research and development of innovative oncology targeted therapies. Furmonertinib mesylate tablets received marketing approval for multiple indications, and the company introduced the KRAS G12C inhibitor glecirasib citrate tablets, with revenue from core products continuing to grow.
Shanghai Allist Pharmaceuticals Co. Ltd. AFirst-half net profit up 46.6% and revenue up 39.9%, with core product revenue growing.
